Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 5/20 | 0.67 |
| ▸ | HTR1D | P28221 | 4/20 | 0.65 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.64 |
| ▸ | EGFR | P00533 | 1/20 | 0.64 |
| ▸ | IGF1R | P08069 | 1/20 | 0.64 |
| ▸ | FLT4 | P35916 | 1/20 | 0.64 |
| ▸ | KDR | P35968 | 1/20 | 0.64 |
| ▸ | HTR6 | P50406 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 2/20 | 0.46 |
| ▸ | DRD3 | P35462 | 2/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 4/20 | 0.43 |
| ▸ | HTR2C | P28335 | 4/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24408213 | 1.00 | HTR1B (0.67) | HTR1BHTR1DNR2E1EGFRIGF1R | |
| SCHEMBL24408397 | 1.00 | HTR1B (0.67) | HTR1BHTR1DNR2E1EGFRIGF1R | |
| SCHEMBL11426192 | 0.88 | NR2E1 (0.64) | HTR1BHTR1DNR2E1EGFRIGF1R | |
| Hydrochloric Acid SCHEMBL11418365 | 0.87 | NR2E1 (0.62) | HTR1BHTR1DNR2E1EGFRIGF1R | |
| SCHEMBL24408304 | 0.84 | HTR1B (0.51) | HTR1BHTR1DNR2E1EGFRIGF1R | |
| SCHEMBL15281767 | 0.84 | HTR1B (0.67) | HTR1BHTR1DNR2E1EGFRIGF1R | |
| SCHEMBL14624295 | 0.84 | HTR1B (0.67) | HTR1BHTR1DNR2E1EGFRIGF1R | |
| SCHEMBL9336395 | 0.82 | HTR1B (0.65) | HTR1BHTR1DNR2E1EGFRIGF1R | |
| SCHEMBL6529421 | 0.82 | HTR1B (0.65) | HTR1BHTR1DNR2E1EGFRIGF1R | |
| SCHEMBL833780 | 0.82 | HTR1B (0.65) | HTR1BHTR1DNR2E1EGFRIGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220144839-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2022-05-12 | — | — | US | disclosed |
| US-20110223166-A1 | Methods for Preventing Pressure-Induced Apoptotic Neural-Cell Death | MINAS THEODORE CORONEO (AU) | 2011-09-15 | — | — | US | disclosed |
| US-20060013814-A1 | Methods for preventing pressure-induced apoptotic neural-cell death | DAVIES COLLISON CAVE (AU) | 2006-01-19 | — | — | US | disclosed |
| US-6380201-B1 | Methods of treating or ameliorating the symptoms of common cold or allergic rhinitis with serotonin 5-HT1F agonists | ELI LILLY AND COMPANY | 2002-04-30 | — | — | US | disclosed |
| EP-0782568-B1 | AROMATIC ETHERS DERIVED FROM INDOLS SUCH AS 5HT1-LIKE LIGANDS | PF MEDICAMENT (FR) | 2002-04-24 | — | — | EP | disclosed |
| EP-0749962-B1 | 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta(7,6-B)indoles | LILLY CO ELI (US) | 2000-11-02 | — | — | EP | disclosed |
| US-5962473-A | Methods of treating or ameliorating the symptoms of common cold or allergic rhinitis with serotonin 5-HT1F | ELI LILLY AND COMPANY (US) | 1999-10-05 | — | — | US | disclosed |
| US-5852049-A | Aromatic ethers derived from indoles which are useful as medicaments | PIERRE FABRE MEDICAMENT (FR) | 1998-12-22 | — | — | US | disclosed |
| US-5814653-A | SUMATRIPTAN FOR RELIEF OF MIGRAINE PAIN AND OTHER DISORDERS ASSOCIATED WITH PEPTIDE EXTRAVASATION DIE TO STUMULATION OF THE TRIGEMINAL GANGLIA; 5-HT 1F AGONISTS | ELI LILLY AND COMPANY (US) | 1998-09-29 | — | — | US | disclosed |
| EP-0832650-A2 | Use of serotonin 5-HT1F agonists for the prevention of migraine | ELI LILLY AND COMPANY (US) | 1998-04-01 | — | — | EP | disclosed |
| EP-0824917-A2 | Use of a serotonin 5-HTlf agonist in the manufacture of a medicament for treating or ameliorating the symptoms of common cold or allergic rhinitis | ELI LILLY AND COMPANY (US) | 1998-02-25 | — | — | EP | disclosed |
| US-5708187-A | MIGRANE HEADACHES | ELI LILLY AND COMPANY (US) | 1998-01-13 | — | — | US | disclosed |
| EP-0782568-A1 | AROMATIC ETHERS DERIVED FROM INDOLS SUCH AS 5HT1-LIKE LIGANDS | PIERRE FABRE MEDICAMENT (FR) | 1997-07-09 | — | — | EP | disclosed |
| EP-0749962-A1 | 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta(7,6-B)indoles | ELI LILLY AND COMPANY (US) | 1996-12-27 | — | — | EP | disclosed |
| WO-1996026936-A1 | NOVEL CYCLIC AMINO-INDOLE PIPERAZINE DERIVATIVES, PREPARATION PROCESS AND UTILIZATION AS MEDICAMENTS | PIERRE FABRE MEDICAMENT (FR) | 1996-09-06 | — | — | WO | disclosed |
| WO-1996009288-A1 | AROMATIC ETHERS DERIVED FROM INDOLS SUCH AS 5HT1-LIKE LIGANDS | PIERRE FABRE MEDICAMENT (FR) | 1996-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144839-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | AHR, ARNT, IDO1 | HTR1B 76/4885HTR1D 179/4885NR2E1 391/4885 |
| US-20060013814-A1 | Methods for preventing pressure-induced apoptotic neural-cell death | BAX, CASP3, BCL2 | HTR1B 2426/4885HTR1D 3251/4885NR2E1 3076/4885 |
| US-20110223166-A1 | Methods for Preventing Pressure-Induced Apoptotic Neural-Cell Death | BAX, CASP3, BCL2 | HTR1B 2426/4885HTR1D 3251/4885NR2E1 3076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.